Pub Date : 2013-09-01DOI: 10.14312/2052-4994.2013-28
Spinelli C, Fregoli L, Biricotti M, Pucci V, Grosso M, O. F, Spisni R, Usolini C, Caldarelli C
Primary neuroendocrine carcinomas of the breast are extremely rare. Neuroendocrine tumors mainly occur in the broncopolmonary system and gastrointestinal tract. The diagnosis of small cell neuroendocrine carcinoma (SCNC) of the breast can only be made if a non mammary site is excluded or if an in situ component can be found. We are going to describe two cases and to discuss their clinical, radiological and pathological manifestations. Introduction: Neuroendocrine tumors are rare and slow-growing neoplasias derived from neuroendocrine cells. We describe two cases of small cell neuroendocrine carcinoma of the breast and discuss their clinical, radiological and pathological manifestations. Case report: Our patients are two Italian females (38 and 36 year-old) with no family history of breast disease. In both cases the diagnosis was confirmed after surgery, when immunohistochemistry revealed a neuroendocrine differentiation of the tumor. The patients are alive and disease free after more than ten years of follow-up. Conclusion: Primary neuroendocrine carcinomas of the breast are extremely rare. The diagnosis of SCNC of the breast can only be made if a non mammary site is excluded or if an in situ component can be found. After surgery, a strict follow-up including octreotide scan should be performed and this doesn’t differ from the one of the usual breast carcinoma.
{"title":"Primary small cell neuroendocrine carcinoma of the breast : a report of two cases and review of literature","authors":"Spinelli C, Fregoli L, Biricotti M, Pucci V, Grosso M, O. F, Spisni R, Usolini C, Caldarelli C","doi":"10.14312/2052-4994.2013-28","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-28","url":null,"abstract":"Primary neuroendocrine carcinomas of the breast are extremely rare. Neuroendocrine tumors mainly occur in the broncopolmonary system and gastrointestinal tract. The diagnosis of small cell neuroendocrine carcinoma (SCNC) of the breast can only be made if a non mammary site is excluded or if an in situ component can be found. We are going to describe two cases and to discuss their clinical, radiological and pathological manifestations. Introduction: Neuroendocrine tumors are rare and slow-growing neoplasias derived from neuroendocrine cells. We describe two cases of small cell neuroendocrine carcinoma of the breast and discuss their clinical, radiological and pathological manifestations. Case report: Our patients are two Italian females (38 and 36 year-old) with no family history of breast disease. In both cases the diagnosis was confirmed after surgery, when immunohistochemistry revealed a neuroendocrine differentiation of the tumor. The patients are alive and disease free after more than ten years of follow-up. Conclusion: Primary neuroendocrine carcinomas of the breast are extremely rare. The diagnosis of SCNC of the breast can only be made if a non mammary site is excluded or if an in situ component can be found. After surgery, a strict follow-up including octreotide scan should be performed and this doesn’t differ from the one of the usual breast carcinoma.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"115 1","pages":"186-193"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80849435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-09-01DOI: 10.14312/2052-4994.2013-27
Hussein Na, M. Anwar, Y. Elkerm, Abozaid Na, Rasha Mm
Big endothelin-1 (big ET-1) is the biological precursor of endothelin-1 (ET-1) and it is known as an indicator for the degree of activation of endothelin system. Therefore, this study was designed to investigate the serum big ET-1 levels in newly diagnosed primary breast cancer patients; before surgery and after adjuvant therapy. In addition this study was also aimed at examining the correlation between big ET-1 and CA15.3, clinical and pathological criteria of breast cancer, as well as their status during the follow up period after adjuvant therapy. The study consisted of 40 females with newly diagnosed primary breast cancer treated at the Medical Research Institute hospital and 15 healthy females as a control group. Before surgery, big ET-1 serum levels of all breast cancer patients were significantly higher than those of the control group (p0.001). However, after both surgery and adjuvant therapy, big ET-1 was significantly decreased compared to its level before surgery (p<0.001). On the other hand, there was lack of significant differences in the levels of CA15.3, neither before surgery nor after the adjuvant therapy in comparison to the control group. Interestingly, during the follow up period, nine patients developed metastasis to different organs and their serum big ET-1 and CA15.3 levels significantly increased compared to the levels before surgery and after the adjuvant therapy (p0.001, 0.008 and 0.001, 0.008 respectively). Inspite of this observation with this specific group of patients, the use of these markers to predict the development of metastasis during the follow up period cannot be generalized. Furthermore, both of these biochemical parameters showed no correlation to any of the clinicopathological parameters and patients characteristics. Therefore, in conclusion this study found that the testing for serum big ET-1 is more useful than CA15.3 for the diagnosis of breast cancer and future trials will be necessary to establish the importance of big ET-1 as a prognostic marker and to formulate a time-line for its measurement in patients with high risk for developing metastasis.
{"title":"Evaluation of serum big endothelin-1 for the diagnosis and prediction of disease recurrence in breast cancer patients","authors":"Hussein Na, M. Anwar, Y. Elkerm, Abozaid Na, Rasha Mm","doi":"10.14312/2052-4994.2013-27","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-27","url":null,"abstract":"Big endothelin-1 (big ET-1) is the biological precursor of endothelin-1 (ET-1) and it is known as an indicator for the degree of activation of endothelin system. Therefore, this study was designed to investigate the serum big ET-1 levels in newly diagnosed primary breast cancer patients; before surgery and after adjuvant therapy. In addition this study was also aimed at examining the correlation between big ET-1 and CA15.3, clinical and pathological criteria of breast cancer, as well as their status during the follow up period after adjuvant therapy. The study consisted of 40 females with newly diagnosed primary breast cancer treated at the Medical Research Institute hospital and 15 healthy females as a control group. Before surgery, big ET-1 serum levels of all breast cancer patients were significantly higher than those of the control group (p0.001). However, after both surgery and adjuvant therapy, big ET-1 was significantly decreased compared to its level before surgery (p<0.001). On the other hand, there was lack of significant differences in the levels of CA15.3, neither before surgery nor after the adjuvant therapy in comparison to the control group. Interestingly, during the follow up period, nine patients developed metastasis to different organs and their serum big ET-1 and CA15.3 levels significantly increased compared to the levels before surgery and after the adjuvant therapy (p0.001, 0.008 and 0.001, 0.008 respectively). Inspite of this observation with this specific group of patients, the use of these markers to predict the development of metastasis during the follow up period cannot be generalized. Furthermore, both of these biochemical parameters showed no correlation to any of the clinicopathological parameters and patients characteristics. Therefore, in conclusion this study found that the testing for serum big ET-1 is more useful than CA15.3 for the diagnosis of breast cancer and future trials will be necessary to establish the importance of big ET-1 as a prognostic marker and to formulate a time-line for its measurement in patients with high risk for developing metastasis.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"99 1","pages":"178-185"},"PeriodicalIF":0.0,"publicationDate":"2013-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81129949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.14312/2052-4994.2013-25
Soriano-García Jl, Á. López-Díaz, M. Solares-Asteasuainzarra, I. Baladrón-Castrillo, N. Batista-Albuerne, I. García-García, L. González-Méndez, Y. Perera-Negrín, C. Valenzuela-Silva, Pedro Ap, Quevedo-Sotolongo Ls, I. Hernández-González, Silveira-Pablos Jm, A. Chong-Lopez, D. Alonso, Renault Jy Gómez Re, P. Perrin, Hugo Sigman, S. Gold, S. E. Perea-Rodríguez, Boris Acevedo-Castro, Luís Herrera-Martínez, P. López-Saura
CIGB-300 is a pro-apoptotic casein kinase 2 inhibitor peptide with potential anticancer action. An open-label and dose scaling Phase I trial was carried out to investigate the peptide tumor uptake, pharmacokinetics, toxicity, and levels of a CIGB-300 response biomarker in patients with cervical cancer stage IB2/II. Fourteen patients were included; six of them received 35 mg, 6 received 70 mg and the two remaining patients received 245 mg of CIGB-300 prior chemoradiotherapy. CIGB-300 was applied by intratumor injections during 5-consecutive days. For pharmacokinetic and biodistribution studies, the peptide was radiolabeled with 99m Tc in the first administration and whole body gammagraphy and plasma testing were done during 48 h. Data showed that the maximum tolerated dose was 70 mg for CIGB-300 in this clinical setting. Furthermore, an allergic-like syndrome was identified as the dose limiting toxicity, which was well-correlated with plasmatic histamine levels. Importantly, the mean tumor uptake was 14.9 mg and 10.4 mg for CIGB-300 doses of 35 and 70 mg, respectively. Also, the kidneys were the main target organ for drug elimination. Finally, treatment with CIGB-300 significantly reduced the B23/nucleophosmin levels in tumor specimens. CIGB-300 meets potentialities to be tested in future trials in a neoadjuvant setting prior to chemoradiotherapy in cervical cancer.
{"title":"Pharmacological and safety evaluation of CIGB-300, a casein kinase 2 inhibitor peptide, administered intralesionally to patients with cervical cancer stage IB2/II","authors":"Soriano-García Jl, Á. López-Díaz, M. Solares-Asteasuainzarra, I. Baladrón-Castrillo, N. Batista-Albuerne, I. García-García, L. González-Méndez, Y. Perera-Negrín, C. Valenzuela-Silva, Pedro Ap, Quevedo-Sotolongo Ls, I. Hernández-González, Silveira-Pablos Jm, A. Chong-Lopez, D. Alonso, Renault Jy Gómez Re, P. Perrin, Hugo Sigman, S. Gold, S. E. Perea-Rodríguez, Boris Acevedo-Castro, Luís Herrera-Martínez, P. López-Saura","doi":"10.14312/2052-4994.2013-25","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-25","url":null,"abstract":"CIGB-300 is a pro-apoptotic casein kinase 2 inhibitor peptide with potential anticancer action. An open-label and dose scaling Phase I trial was carried out to investigate the peptide tumor uptake, pharmacokinetics, toxicity, and levels of a CIGB-300 response biomarker in patients with cervical cancer stage IB2/II. Fourteen patients were included; six of them received 35 mg, 6 received 70 mg and the two remaining patients received 245 mg of CIGB-300 prior chemoradiotherapy. CIGB-300 was applied by intratumor injections during 5-consecutive days. For pharmacokinetic and biodistribution studies, the peptide was radiolabeled with 99m Tc in the first administration and whole body gammagraphy and plasma testing were done during 48 h. Data showed that the maximum tolerated dose was 70 mg for CIGB-300 in this clinical setting. Furthermore, an allergic-like syndrome was identified as the dose limiting toxicity, which was well-correlated with plasmatic histamine levels. Importantly, the mean tumor uptake was 14.9 mg and 10.4 mg for CIGB-300 doses of 35 and 70 mg, respectively. Also, the kidneys were the main target organ for drug elimination. Finally, treatment with CIGB-300 significantly reduced the B23/nucleophosmin levels in tumor specimens. CIGB-300 meets potentialities to be tested in future trials in a neoadjuvant setting prior to chemoradiotherapy in cervical cancer.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"4 2","pages":"163-173"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72462532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.14312/2052-4994.2013-26
N. Ferreira, L. Marais
{"title":"Primary malignant giant cell tumour of the proximal tibia: a case report","authors":"N. Ferreira, L. Marais","doi":"10.14312/2052-4994.2013-26","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-26","url":null,"abstract":"","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"5 1","pages":"174-177"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84057907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-08-01DOI: 10.14312/2052-4994.2013-24
J. Howard, Haixia Cheng, Jimena Pérez, E. Ratner, E. Fertig, M. Considine, M. Ochs, R. Slebos, J. Weidhaas, C. Chung
MicroRNAs (miRNAs) play a critical role in cell cycle and pro-survival signal regulation. Consequently, their deregulation can enhance tumorigenesis and cancer progression. In the current investigation, we determined whether cancer- or human papillomavirus (HPV)-specific miRNA deregulation could further elucidate signal transduction events unique to head and neck squamous cell carcinoma (HNSCC). Twenty-nine newly diagnosed HNSCC tumors (HPV-positive: 14, HPV-negative: 15) and four normal mucosa samples were analyzed for global miRNA expression. Differential miRNA expression analysis concluded HNSCC is characterized by a general upregulation of miRNAs compared to normal mucosa. Additionally, miR-449a and miR-129-3p were statistically significant miRNAs differentially expressed between HPVpositive and HPV-negative HNSCC. The upregulation of miR-449a was also validated within an independent dataset obtained from TCGA containing 279 HNSCCs and 39 normal adjacent mucosa samples. To gain a better understanding of miRNA-mediated cell cycle deregulation in HNSCC, we functionally evaluated miR-205, a transcript upregulated in our cancer-specific analysis and a putative regulator of E2F1. Modulation of miR-205 with a miRNA mimic and inhibitor revealed miR-205 is capable of regulating E2F1 expression in HNSCC and overexpression of this transcript enhances proliferation. This study demonstrates miRNA expression is highly deregulated in HNSCC and functional evaluations of these miRNAs may reveal novel HPV context dependent mechanisms in this disease.
{"title":"miRNA array analysis determines miR-205 is overexpressed in head and neck squamous cell carcinoma and enhances cellular proliferation","authors":"J. Howard, Haixia Cheng, Jimena Pérez, E. Ratner, E. Fertig, M. Considine, M. Ochs, R. Slebos, J. Weidhaas, C. Chung","doi":"10.14312/2052-4994.2013-24","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-24","url":null,"abstract":"MicroRNAs (miRNAs) play a critical role in cell cycle and pro-survival signal regulation. Consequently, their deregulation can enhance tumorigenesis and cancer progression. In the current investigation, we determined whether cancer- or human papillomavirus (HPV)-specific miRNA deregulation could further elucidate signal transduction events unique to head and neck squamous cell carcinoma (HNSCC). Twenty-nine newly diagnosed HNSCC tumors (HPV-positive: 14, HPV-negative: 15) and four normal mucosa samples were analyzed for global miRNA expression. Differential miRNA expression analysis concluded HNSCC is characterized by a general upregulation of miRNAs compared to normal mucosa. Additionally, miR-449a and miR-129-3p were statistically significant miRNAs differentially expressed between HPVpositive and HPV-negative HNSCC. The upregulation of miR-449a was also validated within an independent dataset obtained from TCGA containing 279 HNSCCs and 39 normal adjacent mucosa samples. To gain a better understanding of miRNA-mediated cell cycle deregulation in HNSCC, we functionally evaluated miR-205, a transcript upregulated in our cancer-specific analysis and a putative regulator of E2F1. Modulation of miR-205 with a miRNA mimic and inhibitor revealed miR-205 is capable of regulating E2F1 expression in HNSCC and overexpression of this transcript enhances proliferation. This study demonstrates miRNA expression is highly deregulated in HNSCC and functional evaluations of these miRNAs may reveal novel HPV context dependent mechanisms in this disease.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"258 1","pages":"153-162"},"PeriodicalIF":0.0,"publicationDate":"2013-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86714162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-07-01DOI: 10.14312/2052-4994.2013-22
Zhong Nb, Chen Zh, L'vitsina Gm
Purposes: Hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT) has a poor prognosis, while the optimal treatment remains controversial. The objective of this retrospective study was to evaluate the efficacy and safety of ray SBRT in treatment of patients with HCC-PVTT. Methods: The study was designed to examine the effects of ray SBRT on toxicity and survival in patients with HCC-PVTT. To this end, data from patients with HCC-PVTT who received ray SBRT during May 2008 to December 2011 was collected and analyzed. Response and (acute and late) toxicity were evaluated using the established international criteria. Log-rank test and Cox regression model were used to identify predictive factors and multivariate for survival, respectively. Results: The median follow up was 11 months. Fifty four consecutive patients with HCC-PVTT received daily fraction of 2.6 6Gy and six fractions per week for the total dose of 32.4 54Gy in 6 13 days. Six complete response (CR; 11.1%) and twenty five partial response (PR; 46.3%) were observed (overall response rate 57.4%). Twenty three patients displayed a stable disease (SD; 42.6%), while no patient experienced progressive disease (PD; 0%). The treatment was well tolerated with no radiation-related complication and no Grade 3 toxicity. Oneand twoyear overall survival rate were 33.4% and 13.6% respectively, and median overall survival was 10.7 months. The prognostic factors for survival included ECOG performance status (P0.04), Child-Pugh score (P0.05), PVTT size (P0.02) and location (P0.05). Conclusions: Individual ray SBRT appears to be feasible for treatment of patients with HCC-PVTT in whom other current therapies are contraindicated. PVTT size and ECOG performance status may represent the strongest predictive factors for survival.
{"title":"A clinical study on stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis","authors":"Zhong Nb, Chen Zh, L'vitsina Gm","doi":"10.14312/2052-4994.2013-22","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-22","url":null,"abstract":"Purposes: Hepatocellular carcinoma with portal vein tumor thrombosis (HCC-PVTT) has a poor prognosis, while the optimal treatment remains controversial. The objective of this retrospective study was to evaluate the efficacy and safety of ray SBRT in treatment of patients with HCC-PVTT. Methods: The study was designed to examine the effects of ray SBRT on toxicity and survival in patients with HCC-PVTT. To this end, data from patients with HCC-PVTT who received ray SBRT during May 2008 to December 2011 was collected and analyzed. Response and (acute and late) toxicity were evaluated using the established international criteria. Log-rank test and Cox regression model were used to identify predictive factors and multivariate for survival, respectively. Results: The median follow up was 11 months. Fifty four consecutive patients with HCC-PVTT received daily fraction of 2.6 6Gy and six fractions per week for the total dose of 32.4 54Gy in 6 13 days. Six complete response (CR; 11.1%) and twenty five partial response (PR; 46.3%) were observed (overall response rate 57.4%). Twenty three patients displayed a stable disease (SD; 42.6%), while no patient experienced progressive disease (PD; 0%). The treatment was well tolerated with no radiation-related complication and no Grade 3 toxicity. Oneand twoyear overall survival rate were 33.4% and 13.6% respectively, and median overall survival was 10.7 months. The prognostic factors for survival included ECOG performance status (P0.04), Child-Pugh score (P0.05), PVTT size (P0.02) and location (P0.05). Conclusions: Individual ray SBRT appears to be feasible for treatment of patients with HCC-PVTT in whom other current therapies are contraindicated. PVTT size and ECOG performance status may represent the strongest predictive factors for survival.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"150 1","pages":"143-148"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76404719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-07-01DOI: 10.14312/2052-4994.2013-23
D. Wamala, P. Kitayimbwa, O. Dworak
Introduction: Rhabdomyosarcoma is the commonest soft tissue sarcoma of childhood. The tumour commonly occurs in the body regions of the head and neck, genitourinary and extremities. Primary rhabdomyosarcoma of the breast is extremely rare and present diagnostic challenges especially in resource limited centers. It is an aggressive tumour with a poor prognosis especially when diagnosed late. Case presentation: We present a case of 13 year old female with primary rhabdomyosarcoma of breast metastasized to regional axillary lymph nodes, lung and heart. The patient failed to respond to chemotherapy mainly due diagnostic challenges and succumbed to the disease. Conclusion: Breast masses in young patients should be diagnosed early and accurately, and optimal treatment promptly instituted. The incidence of primary rhabdomyosarcoma of breast is increasing in teenagers, and the tumour has a bad prognosis especially in late stage. We think this case will add knowledge and skills required in histological and cytological diagnosis of breast rhabdomyosarcoma.
{"title":"Primary alveolar rhabdomyosarcoma of breast in a 13 year old female with cardiopulmonary metastases and cyto-histological correlation: A case report","authors":"D. Wamala, P. Kitayimbwa, O. Dworak","doi":"10.14312/2052-4994.2013-23","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-23","url":null,"abstract":"Introduction: Rhabdomyosarcoma is the commonest soft tissue sarcoma of childhood. The tumour commonly occurs in the body regions of the head and neck, genitourinary and extremities. Primary rhabdomyosarcoma of the breast is extremely rare and present diagnostic challenges especially in resource limited centers. It is an aggressive tumour with a poor prognosis especially when diagnosed late. Case presentation: We present a case of 13 year old female with primary rhabdomyosarcoma of breast metastasized to regional axillary lymph nodes, lung and heart. The patient failed to respond to chemotherapy mainly due diagnostic challenges and succumbed to the disease. Conclusion: Breast masses in young patients should be diagnosed early and accurately, and optimal treatment promptly instituted. The incidence of primary rhabdomyosarcoma of breast is increasing in teenagers, and the tumour has a bad prognosis especially in late stage. We think this case will add knowledge and skills required in histological and cytological diagnosis of breast rhabdomyosarcoma.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"6 1","pages":"149-152"},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90578888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01Epub Date: 2013-05-29DOI: 10.14312/2052-4994.2013-20
V Galitovskiy, S A Kuruvilla, E Sevriokov, A Corches, M L Pan, M Kalantari-Dehaghi, A I Chernyavsky, J Mukherjee, S A Grando
Development of novel methods of early diagnosis of lung cancer is one of the major tasks of contemporary clinical and experimental oncology. In this study, we utilized the tobacco nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung cancer in A/J mice as an animal model for development of a new imaging technique for early diagnosis of lung cancer. Lung cancer cells in A/J mice overexpress nicotinic acetylcholine receptors. Longitudinal CT scans were carried out over a period of 8 months after NNK treatment, followed by PET/CT scans with 18F-Nifene that binds to α4-made nicotinic receptors with high affinity. PET/CT scans of lungs were also obtained ex vivo. CT revealed the presence of lung nodules in 8-month NNK-treated mice, while control mice had no tumors. Imaging of live animals prior to necropsy allowed correlation of results of tumor load via PET/CT and histopathological findings. Significant amount of 18F-Nifene was seen in the lungs of NNK-treated mice, whereas lungs of control mice showed only minor uptake of 18F-Nifene. Quantitative analysis of the extent and amount of 18F-Nifene binding in lung in vivo and ex vivo demonstrated a higher tumor/nontumor ratio due to selective labeling of tumor nodules expressing abundant α4 nicotinic receptor subunits. For comparison, we performed PET/CT studies with 18F-FDG, which is used for the imaging diagnosis of lung cancer. The tumor/nontumor ratios for 18F-FDG were lower than for 18F-Nifene. Thus, we have developed a novel diagnostic imaging approach to early diagnosis of lung cancer using 18F-Nifene PET/CT. This technique allows quantitative assessment of lung tumors in live mice, which is critical for establishing tumor size and location, and also has salient clinical implications.
{"title":"Development of novel approach to diagnostic imaging of lung cancer with <sup>18</sup>F-Nifene PET/CT using A/J mice treated with NNK.","authors":"V Galitovskiy, S A Kuruvilla, E Sevriokov, A Corches, M L Pan, M Kalantari-Dehaghi, A I Chernyavsky, J Mukherjee, S A Grando","doi":"10.14312/2052-4994.2013-20","DOIUrl":"10.14312/2052-4994.2013-20","url":null,"abstract":"<p><p>Development of novel methods of early diagnosis of lung cancer is one of the major tasks of contemporary clinical and experimental oncology. In this study, we utilized the tobacco nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-induced lung cancer in A/J mice as an animal model for development of a new imaging technique for early diagnosis of lung cancer. Lung cancer cells in A/J mice overexpress nicotinic acetylcholine receptors. Longitudinal CT scans were carried out over a period of 8 months after NNK treatment, followed by PET/CT scans with <sup>18</sup>F-Nifene that binds to <i>α</i>4-made nicotinic receptors with high affinity. PET/CT scans of lungs were also obtained <i>ex vivo.</i> CT revealed the presence of lung nodules in 8-month NNK-treated mice, while control mice had no tumors. Imaging of live animals prior to necropsy allowed correlation of results of tumor load <i>via</i> PET/CT and histopathological findings. Significant amount of <sup>18</sup>F-Nifene was seen in the lungs of NNK-treated mice, whereas lungs of control mice showed only minor uptake of <sup>18</sup>F-Nifene. Quantitative analysis of the extent and amount of <sup>18</sup>F-Nifene binding in lung <i>in vivo</i> and <i>ex vivo</i> demonstrated a higher tumor/nontumor ratio due to selective labeling of tumor nodules expressing abundant <i>α</i>4 nicotinic receptor subunits. For comparison, we performed PET/CT studies with <sup>18</sup>F-FDG, which is used for the imaging diagnosis of lung cancer. The tumor/nontumor ratios for <sup>18</sup>F-FDG were lower than for <sup>18</sup>F-Nifene. Thus, we have developed a novel diagnostic imaging approach to early diagnosis of lung cancer using <sup>18</sup>F-Nifene PET/CT. This technique allows quantitative assessment of lung tumors in live mice, which is critical for establishing tumor size and location, and also has salient clinical implications.</p>","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"1 4","pages":"128-137"},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443253/pdf/nihms860940.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35035802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-06-01DOI: 10.14312/2052-4994.2013-21
Ogasawara T, Aiba M, Kawauchi K
This report describes a case of a patient who developed therapy-related acute myeloid leukemia five years after initiating chemotherapy for follicular lymphoma. The patient had been treated with multiple chemotherapeutic regimens, including anthracycline and etoposide (VP-16), as well as with radiation therapy for refractory follicular lymphoma over the preceding five years. The patient subsequently developed myelodysplastic syndrome (MDS) with karyotypic abnormalities of monosomy 7 and del (20) (q11; q13.3) followed by acute myeloid leukemia (AML) with an additional balanced translocation of t(9;22)(q34;q11) and t(3;21)(q26;q22). Reverse transcriptionpolymerase chain reaction amplification of the patient’s RNA showed a fusion transcript of minor BCR-ABL but not EVI1-RUNX1 (AML1) genes. Imatinib therapy resulted in regression of AML, but the patient soon became refractory to chemotherapy and died. Therapy-related acute leukemia develops mostly as non-lymphoid leukemia with unbalanced aberrations of monosomy 7 and 5 or balanced aberrations involving 11q23 and 21q22, but Philadelphia chromosome is uncommon. In addition, simultaneous occurrence of both t(9;22)(q34;q11) and t(3;21)(q26;q22) balanced aberrations in t-MDS/t-AML is a very rare event. The balanced translocations detected in this case suggest another mechanism by which t-AML can develop after chemotherapy and radiation therapy for follicular lymphoma.
{"title":"Therapy-related acute myeloid leukemia with chromosomal abnormalities involving t(9;22)(q34;q11) and t(3;21)(q26;q22) during chemotherapy for follicular lymphoma","authors":"Ogasawara T, Aiba M, Kawauchi K","doi":"10.14312/2052-4994.2013-21","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-21","url":null,"abstract":"This report describes a case of a patient who developed therapy-related acute myeloid leukemia five years after initiating chemotherapy for follicular lymphoma. The patient had been treated with multiple chemotherapeutic regimens, including anthracycline and etoposide (VP-16), as well as with radiation therapy for refractory follicular lymphoma over the preceding five years. The patient subsequently developed myelodysplastic syndrome (MDS) with karyotypic abnormalities of monosomy 7 and del (20) (q11; q13.3) followed by acute myeloid leukemia (AML) with an additional balanced translocation of t(9;22)(q34;q11) and t(3;21)(q26;q22). Reverse transcriptionpolymerase chain reaction amplification of the patient’s RNA showed a fusion transcript of minor BCR-ABL but not EVI1-RUNX1 (AML1) genes. Imatinib therapy resulted in regression of AML, but the patient soon became refractory to chemotherapy and died. Therapy-related acute leukemia develops mostly as non-lymphoid leukemia with unbalanced aberrations of monosomy 7 and 5 or balanced aberrations involving 11q23 and 21q22, but Philadelphia chromosome is uncommon. In addition, simultaneous occurrence of both t(9;22)(q34;q11) and t(3;21)(q26;q22) balanced aberrations in t-MDS/t-AML is a very rare event. The balanced translocations detected in this case suggest another mechanism by which t-AML can develop after chemotherapy and radiation therapy for follicular lymphoma.","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"128 1","pages":"138-142"},"PeriodicalIF":0.0,"publicationDate":"2013-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76061980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2013-05-01DOI: 10.14312/2052-4994.2013-17
K. Kendall, M. Repp, T. Jilka, K. Kingsley
{"title":"Biomarker screening of oral cancer cell lines revealed sub-populations of CD133-, CD44-, CD24- and ALDH1- positive cancer stem cells","authors":"K. Kendall, M. Repp, T. Jilka, K. Kingsley","doi":"10.14312/2052-4994.2013-17","DOIUrl":"https://doi.org/10.14312/2052-4994.2013-17","url":null,"abstract":"","PeriodicalId":90205,"journal":{"name":"Journal of cancer research & therapy","volume":"29 1","pages":"111-118"},"PeriodicalIF":0.0,"publicationDate":"2013-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77944236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：